Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly EXPEDITION data puts some flesh on solanezumab's bones

This article was originally published in Scrip

Executive Summary

The full data from Lilly's mixed EXPEDITION studies for its anti-amyloid Alzheimer's disease monoclonal antibody (MAb) candidate solanezumab have now been presented, bringing some clarity on the extent of the significant effects seen on some of the endpoint measures tested in the pivotal programme.